LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Book ; Conference proceedings: Hereditary breast, ovarian, and colon cancer

    Giusti, Ruthann M

    proceedings of a workshop held ... Washington, D.C., April 27 - 29, 1994

    (Journal of the National Cancer Institute : Monographs ; 17)

    1995  

    Event/congress Workshop "Hereditary Breast, Ovarian, and Colon Cancer" (1994.04.27-29, Washington)
    Author's details eds.: Ruthann M. Giusti
    Series title Journal of the National Cancer Institute : Monographs ; 17
    Language English
    Size VII, 137 S., graph. Darst.
    Publisher US Government Printing Office
    Publishing place Washington, DC
    Document type Book ; Conference proceedings
    Note Literaturangaben
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  2. Article ; Online: FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.

    Giusti, Ruthann M / Cohen, Martin H / Keegan, Patricia / Pazdur, Richard

    The oncologist

    2009  Volume 14, Issue 3, Page(s) 284–290

    Abstract: On September 27, 2006, the U.S. Food and Drug Administration granted accelerated approval to panitumumab (Vectibix; Amgen, Inc., Thousand Oaks, CA) for the treatment of patients with epidermal growth factor receptor-expressing, metastatic colorectal ... ...

    Abstract On September 27, 2006, the U.S. Food and Drug Administration granted accelerated approval to panitumumab (Vectibix; Amgen, Inc., Thousand Oaks, CA) for the treatment of patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Accelerated approval was based on demonstration of a beneficial effect on progression-free survival (PFS). The present submission summarizes a second clinical trial, to be included in the panitumumab package insert in June 2008, of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. The study was closed when inferior PFS and greater toxicity were demonstrated at the time of the planned interim efficacy analysis. Patients receiving panitumumab in combination with bevacizumab and chemotherapy experienced a higher incidence of death (9% versus 4%) and a higher risk for grade 3 and 4 toxicities than patients receiving bevacizumab and chemotherapy alone. The incidences of any Common Terminology Criteria for Adverse Events grade 3 and 4 adverse events (AEs) were 87% and 72% in the panitumumab and control groups, respectively. Grade 3 and 4 AEs occurring more commonly in panitumumab-treated patients included rash/acneiform dermatitis, diarrhea, dehydration, primarily resulting from diarrhea, hypokalemia, stomatitis/mucositis, and pulmonary embolism. The addition of panitumumab to bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer was harmful when compared with bevacizumab and chemotherapy alone. The use of panitumumab in this setting cannot be recommended.
    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Disease-Free Survival ; Drug Approval ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Treatment Outcome ; United States ; United States Food and Drug Administration
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Organoplatinum Compounds ; oxaliplatin (04ZR38536J) ; Bevacizumab (2S9ZZM9Q9V) ; panitumumab (6A901E312A) ; irinotecan (7673326042) ; Fluorouracil (U3P01618RT) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 2009-03
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1634/theoncologist.2008-0254
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Deliberate deceit of family members: a challenge to providers of clinical genetics services.

    Loud, Jennifer T / Weissman, Nancy E / Peters, June A / Giusti, Ruthann M / Wilfond, Benjamin S / Burke, Wylie / Greene, Mark H

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2006  Volume 24, Issue 10, Page(s) 1643–1646

    MeSH term(s) Confidentiality ; Female ; Genes, BRCA1 ; Genetic Counseling ; Genetic Testing/ethics ; Humans ; Middle Aged ; Mutation
    Language English
    Publishing date 2006-04-01
    Publishing country United States
    Document type Letter
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2005.02.6203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: FDA drug approval summary: panitumumab (Vectibix).

    Giusti, Ruthann M / Shastri, Kaushikkumar A / Cohen, Martin H / Keegan, Patricia / Pazdur, Richard

    The oncologist

    2007  Volume 12, Issue 5, Page(s) 577–583

    Abstract: On September 27, 2006, the U.S. Food and Drug Administration granted approval to panitumumab (Vectibix, Amgen, Inc., Thousand Oaks, CA) for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma ...

    Abstract On September 27, 2006, the U.S. Food and Drug Administration granted approval to panitumumab (Vectibix, Amgen, Inc., Thousand Oaks, CA) for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab approval is based on the results of a single, open-label, randomized, multinational study that enrolled 463 patients with EGFR-expressing (at least 1+ membrane staining in > or =1% of tumor cells) metastatic colorectal cancer. Patients were randomized to either best supportive care (BSC) alone or BSC plus panitumumab, 6 mg/kg i.v., every other week. The primary study endpoint was progression-free survival (PFS), determined by an independent review committee that was blinded as to treatment assignment. BSC patients who progressed were eligible to receive panitumumab. The study patients' median age was 62 years, with 40% aged > or =65; 63% were male, 99% were white, 86% had a baseline Eastern Cooperative Oncology Group performance status score of 0 or 1, and 67% had colon cancer. The median time from diagnosis of metastases was approximately 19 months and the median number of prior therapies was 2.4. The PFS duration was significantly longer among patients randomized to receive panitumumab in addition to BSC (n = 231) compared with BSC alone (n = 232). The median and mean PFS times were 56 and 96.4 days, respectively, for patients receiving panitumumab and 51 and 59.7 days, respectively, for patients receiving BSC alone. Nineteen partial responses (8%, 95% confidence interval [CI], 5.3%-12.5%) were observed in panitumumab treated patients. The median duration of response was 17 weeks (95% CI, 16-25 weeks). Approximately 75% of patients in the BSC alone arm crossed over to receive panitumumab after disease progression. There was no difference in overall survival between the two study arms. The most common adverse events were skin rash, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea, and diarrhea. The most serious adverse events were pulmonary fibrosis, severe dermatologic toxicity complicated by infectious sequelae and septic death, infusion reactions, abdominal pain, hypomagnesemia, nausea, vomiting, diarrhea, and constipation.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Disease Progression ; Disease-Free Survival ; Drug Approval ; Female ; Follow-Up Studies ; Humans ; Infusions, Intravenous ; Lymphatic Metastasis ; Male ; Middle Aged ; Palliative Care ; Receptor, Epidermal Growth Factor/biosynthesis ; Receptor, Epidermal Growth Factor/drug effects ; Receptor, Epidermal Growth Factor/metabolism ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; panitumumab (6A901E312A) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1)
    Language English
    Publishing date 2007-05
    Publishing country United States
    Document type Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 1409038-7
    ISSN 1083-7159
    ISSN 1083-7159
    DOI 10.1634/theoncologist.12-5-577
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book ; Conference proceedings: Hereditary breast, ovarian, and colon cancer

    Giusti, Ruthann M / Nayfield, Susan G

    proceedings of a workshop held at the Sheraton Washington Hotel, Washington, D.C., April 27-29, 1994

    (Journal of the National Cancer Institute. Monographs, ; no. 17 ; NIH publication ; no. 94-03837)

    1995  

    Institution National Cancer Institute (U.S.)
    National Center for Human Genome Research (U.S.)
    Event/congress Workshop on Hereditary Breast, Ovarian, and Colon Cancer (1994, WashingtonD.C.)
    Author's details sponsors, National Cancer Institute, National Center for Human Genome Research ; scientific editors, Ruthann M. Giusti, Susan G. Nayfield
    Series title Journal of the National Cancer Institute. Monographs, ; no. 17
    NIH publication ; no. 94-03837
    MeSH term(s) Breast Neoplasms/genetics ; Colonic Neoplasms/genetics ; Genetic Testing/methods ; Ovarian Neoplasms/genetics
    Language English
    Size vii, 137 p. :, ill.
    Publisher National Cancer Institute
    Publishing place Bethesda, MD
    Document type Book ; Conference proceedings
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  6. Article ; Online: BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.

    Bakos, Alexis D / Hutson, Sadie P / Loud, Jennifer T / Peters, June A / Giusti, Ruthann M / Greene, Mark H

    Health expectations : an international journal of public participation in health care and health policy

    2008  Volume 11, Issue 3, Page(s) 220–231

    Abstract: Background: When women from families with a known BRCA1 or BRCA2 mutation test negative for the family mutation, it is assumed that they will transition their personal cancer risk perception from high to average risk. However, there are scant data ... ...

    Abstract Background: When women from families with a known BRCA1 or BRCA2 mutation test negative for the family mutation, it is assumed that they will transition their personal cancer risk perception from high to average risk. However, there are scant data regarding the experience of mutation-negative women after genetic testing disclosure, particularly related to the shift of risk perception from assumed mutation-positive to actual mutation-negative. This study was designed to explore cancer risk perception and the experience of being a mutation-negative woman within a known BRCA1/2 mutation-positive family.
    Methods: We employed a qualitative descriptive design and convened a sample of 13 women who contributed in-depth, semi-structured telephone interviews (audio-recorded and transcribed verbatim) and performed qualitative content analysis with NVivo 2.0 software.
    Results: Six major content areas emerged from interview data: (i) rationale for initial involvement in the breast imaging study, (ii) rationale for continued participation, (iii) experience of living in a multiple-case family, (iv) risk perception: the personal meaning of mutation-negative status, (v) opinions regarding cancer aetiology and (vi) communication patterns between mutation-negative and mutation-positive family members.
    Conclusions: Living in a hereditary breast and ovarian cancer family is a complex experience that affects cognitive, emotional and social functioning. Our findings indicate that mutation-negative women may have unmet psychosocial needs that must be addressed by health-care professionals, particularly in the primary-care setting following genetic disclosure of a potentially reassuring result regarding their lack of the very high cancer risks associated with BRCA1/2 mutations.
    MeSH term(s) Adult ; Affect ; Altruism ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Breast Neoplasms/genetics ; Breast Neoplasms/psychology ; Cognition ; Communication ; Decision Making ; Family Health ; Female ; Genetic Counseling ; Genetic Predisposition to Disease/psychology ; Genetic Testing ; Health Knowledge, Attitudes, Practice ; Humans ; Middle Aged ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/psychology ; Qualitative Research ; Risk Assessment
    Chemical Substances BRCA1 Protein ; BRCA2 Protein
    Language English
    Publishing date 2008-09-24
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural
    ZDB-ID 2119434-8
    ISSN 1369-7625 ; 1369-6513
    ISSN (online) 1369-7625
    ISSN 1369-6513
    DOI 10.1111/j.1369-7625.2008.00494.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer?

    Loud, Jennifer T / Thiébaut, Anne C M / Abati, Andrea D / Filie, Armando C / Nichols, Kathryn / Danforth, David / Giusti, Ruthann / Prindiville, Sheila A / Greene, Mark H

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

    2009  Volume 18, Issue 4, Page(s) 1243–1251

    Abstract: Purpose: Ductal lavage has been used for risk stratification and biomarker development and to identify intermediate endpoints for risk-reducing intervention trials. Little is known about patient characteristics associated with obtaining nipple aspirate ... ...

    Abstract Purpose: Ductal lavage has been used for risk stratification and biomarker development and to identify intermediate endpoints for risk-reducing intervention trials. Little is known about patient characteristics associated with obtaining nipple aspirate fluid (NAF) and adequate cell counts (> or =10 cells) in ductal lavage specimens from BRCA mutation carriers.
    Methods: We evaluated patient characteristics associated with obtaining NAF and adequate cell counts in ductal lavage specimens from the largest cohort of women from BRCA families yet studied (BRCA1/2 = 146, mutation-negative = 23, untested = 2). Fisher's exact test was used to evaluate categorical variables; Wilcoxon nonparametric test was used to evaluate continuous variables associated with NAF or ductal lavage cell count adequacy. Logistic regression was used to identify independent correlates of NAF and ductal lavage cell count adequacy.
    Results: From 171 women, 45 (26%) women had NAF and 70 (41%) women had ductal lavage samples with > or =10 cells. Postmenopausal women with intact ovaries compared with premenopausal women [odds ratio (OR), 4.8; P = 0.03] and women without a prior breast cancer history (OR, 5.2; P = 0.04) had an increased likelihood of yielding NAF. Having breast-fed (OR, 3.4; P = 0.001), the presence of NAF before ductal lavage (OR, 3.2; P = 0.003), and being premenopausal (OR, 3.0; P = 0.003) increased the likelihood of ductal lavage cell count adequacy. In known BRCA1/2 mutation carriers, only breast-feeding (OR, 2.5; P = 0.01) and the presence of NAF (OR, 3.0; P = 0.01) were independent correlates of ductal lavage cell count adequacy.
    Conclusions: Ductal lavage is unlikely to be useful in breast cancer screening among BRCA1/2 mutation carriers because the procedure fails to yield adequate specimens sufficient for reliable cytologic diagnosis or to support translational research activities.
    MeSH term(s) Adult ; Biomarkers, Tumor ; Body Fluids/cytology ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Carcinoma, Ductal, Breast/diagnosis ; Carcinoma, Ductal, Breast/genetics ; Cohort Studies ; Epithelial Cells/pathology ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic Predisposition to Disease/genetics ; Genetic Testing ; Humans ; Middle Aged ; Nipples/pathology ; Prognosis ; Risk Factors ; Therapeutic Irrigation
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2009-03-31
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1153420-5
    ISSN 1055-9965
    ISSN 1055-9965
    DOI 10.1158/1055-9965.EPI-08-0795
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

    Giusti, Ruthann M / Shastri, Kaushikkumar / Pilaro, Anne M / Fuchs, Chana / Cordoba-Rodriguez, Ruth / Koti, Kallappa / Rothmann, Mark / Men, Angela Yuxin / Zhao, Hong / Hughes, Monica / Keegan, Patricia / Weiss, Karen D / Pazdur, Richard

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2008  Volume 14, Issue 5, Page(s) 1296–1302

    Abstract: Purpose: To describe the Food and Drug Administration review and marketing approval considerations for panitumumab (Vectibix) for the third-line treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal carcinoma.: ... ...

    Abstract Purpose: To describe the Food and Drug Administration review and marketing approval considerations for panitumumab (Vectibix) for the third-line treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal carcinoma.
    Experimental design: Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity. Progression and response were confirmed by an independent review committee masked to treatment assignment. At progression, patients in the BSC-alone arm were eligible to receive panitumumab.
    Results: Although median progression-free survival (PFS) was similar in both treatment arms ( approximately 8 weeks), the mean PFS was approximately 50% longer among patients receiving panitumumab than among those receiving BSC alone (96 versus 60 days, respectively) and the objective response rate in patients receiving panitumumab was 8%. However, no difference in overall survival was shown between the two study arms.
    Conclusions: Panitumumab received accelerated approval based on improvement in PFS and an independently confirmed response rate of 8%, similar to that observed with other active agents at this advanced stage of disease. Confirmation of clinical benefit will be required for full approval.
    MeSH term(s) Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Chemotherapy, Adjuvant ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Disease Progression ; Disease-Free Survival ; Drug Approval ; Fluorouracil/administration & dosage ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/metabolism ; Liver Neoplasms/secondary ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/secondary ; Lymphatic Metastasis ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Receptor, Epidermal Growth Factor/metabolism ; Survival Rate ; United States ; United States Food and Drug Administration
    Chemical Substances Antibodies, Monoclonal ; Organoplatinum Compounds ; oxaliplatin (04ZR38536J) ; panitumumab (6A901E312A) ; irinotecan (7673326042) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Fluorouracil (U3P01618RT) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 2008-03-01
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-07-1354
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.

    Rutter, Joni L / Smith, Amelia M / Dávila, Michael R / Sigurdson, Alice J / Giusti, Ruthann M / Pineda, Marbin A / Doody, Michele M / Tucker, Margaret A / Greene, Mark H / Zhang, Jinghui / Struewing, Jeffery P

    Human mutation

    2003  Volume 22, Issue 2, Page(s) 121–128

    Abstract: Two potential breast cancer susceptibility genes, encoding the BRCA1-interacting proteins ZNF350 (or ZBRK1) and BRIP1 (or BACH1), have been identified in yeast two-hybrid screens. We sequenced these genes in probands from 21 families with potentially ... ...

    Abstract Two potential breast cancer susceptibility genes, encoding the BRCA1-interacting proteins ZNF350 (or ZBRK1) and BRIP1 (or BACH1), have been identified in yeast two-hybrid screens. We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer, all of which were negative for BRCA1/BRCA2 mutations. Families had at least one case of male breast cancer, two cases of ovarian cancer, or three or more cases of breast and ovarian cancer. In addition, 58 early-onset (before age 35) breast cancer cases and 30 reference individuals were analyzed. Of 17 variants detected in ZBRK1, a missense mutation Val524Ile was identified in the proband of one high-risk family, but no other family members were available for testing. Of 25 variants identified in BRIP1, in addition to four common silent or missense mutations, we identified Gln540Leu, a non-conservative amino acid change, in a single familial proband with inflammatory breast cancer, but this mutation was not present in her three relatives with breast cancer. Haplotype analysis suggests that all ZBRK1 SNPs fall within a single block with two SNPs capturing 92% of the haplotype diversity, while the BRIP1 SNPs fall in two blocks, with five SNPs capturing 89% of the haplotype diversity. Based on sequencing of ZBRK1 and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families, it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer. Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population. Hum Mutat 22:121-128, 2003. Published 2003 Wiley-Liss, Inc.
    MeSH term(s) BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Basic-Leucine Zipper Transcription Factors ; Breast Neoplasms/genetics ; Breast Neoplasms, Male/genetics ; DNA Mutational Analysis/methods ; DNA, Neoplasm/genetics ; DNA-Binding Proteins ; Family ; Fanconi Anemia Complementation Group Proteins ; Female ; Gene Expression Regulation/genetics ; Gene Expression Regulation/physiology ; Gene Expression Regulation, Neoplastic/genetics ; Genes, BRCA1 ; Genes, BRCA2 ; Haplotypes/genetics ; Humans ; Leucine Zippers/genetics ; Linkage Disequilibrium/genetics ; Male ; Mutation, Missense/genetics ; Ovarian Neoplasms/genetics ; Pedigree ; Repressor Proteins/genetics ; Repressor Proteins/physiology ; Transcription Factors/genetics ; Transcription Factors/physiology ; Zinc Fingers/genetics
    Chemical Substances BACH1 protein, human ; BRCA1 Protein ; BRCA2 Protein ; Basic-Leucine Zipper Transcription Factors ; DNA, Neoplasm ; DNA-Binding Proteins ; Fanconi Anemia Complementation Group Proteins ; Repressor Proteins ; Transcription Factors ; ZNF350 protein, human
    Language English
    Publishing date 2003-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1126646-6
    ISSN 1098-1004 ; 1059-7794
    ISSN (online) 1098-1004
    ISSN 1059-7794
    DOI 10.1002/humu.10238
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top